Development of medications for the treatment of opiate and cocaine addictions: issues for the government and private sector
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Washington, DC
National Acad. Press
1995
|
| Schlagworte: | |
| Beschreibung: | XVII, 250 S. graph. Darst. |
| ISBN: | 0309052440 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV010629404 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 960223s1995 d||| |||| 00||| eng d | ||
| 020 | |a 0309052440 |9 0-309-05244-0 | ||
| 035 | |a (OCoLC)31944782 | ||
| 035 | |a (DE-599)BVBBV010629404 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 050 | 0 | |a RC566 | |
| 082 | 0 | |a 616.86/32061 |2 20 | |
| 084 | |a YH 3015 |0 (DE-625)153535:12921 |2 rvk | ||
| 245 | 1 | 0 | |a Development of medications for the treatment of opiate and cocaine addictions |b issues for the government and private sector |c Committee to Study Medication Development and Research at the National Institute on Drug Abuse, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine. Carolyn E. Fulco ..., ed. |
| 264 | 1 | |a Washington, DC |b National Acad. Press |c 1995 | |
| 300 | |a XVII, 250 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 610 | 2 | 4 | |a National Institute on Drug Abuse |
| 650 | 4 | |a Cocaine abuse |x Treatment | |
| 650 | 4 | |a Cocaine |z United States | |
| 650 | 4 | |a Drug Industry |z United States | |
| 650 | 4 | |a Drug addiction |x Treatment | |
| 650 | 4 | |a Legislation, Drug |z United States | |
| 650 | 4 | |a Narcotics |z United States | |
| 650 | 4 | |a Substance abuse |x Treatment | |
| 650 | 4 | |a Substance-Related Disorders |x drug therapy |z United States | |
| 650 | 0 | 7 | |a Cocain |0 (DE-588)4128249-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Opiate |0 (DE-588)4075669-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Drogentherapie |0 (DE-588)4122122-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Drogenabhängigkeit |0 (DE-588)4138597-4 |2 gnd |9 rswk-swf |
| 651 | 4 | |a USA | |
| 689 | 0 | 0 | |a Drogenabhängigkeit |0 (DE-588)4138597-4 |D s |
| 689 | 0 | 1 | |a Opiate |0 (DE-588)4075669-5 |D s |
| 689 | 0 | 2 | |a Drogentherapie |0 (DE-588)4122122-9 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Drogenabhängigkeit |0 (DE-588)4138597-4 |D s |
| 689 | 1 | 1 | |a Cocain |0 (DE-588)4128249-8 |D s |
| 689 | 1 | 2 | |a Drogentherapie |0 (DE-588)4122122-9 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Fulco, Carolyn E. |e Sonstige |4 oth | |
| 710 | 2 | |a Institute of Medicine (Washington, DC) |b Committee to Study Medication Development and Research at the National Institute on Drug Abuse |e Sonstige |0 (DE-588)1601098-X |4 oth | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-007090681 | ||
Datensatz im Suchindex
| _version_ | 1804125103438430208 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV010629404 |
| callnumber-first | R - Medicine |
| callnumber-label | RC566 |
| callnumber-raw | RC566 |
| callnumber-search | RC566 |
| callnumber-sort | RC 3566 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | YH 3015 |
| ctrlnum | (OCoLC)31944782 (DE-599)BVBBV010629404 |
| dewey-full | 616.86/32061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.86/32061 |
| dewey-search | 616.86/32061 |
| dewey-sort | 3616.86 532061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02336nam a2200565 c 4500</leader><controlfield tag="001">BV010629404</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">960223s1995 d||| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309052440</subfield><subfield code="9">0-309-05244-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)31944782</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV010629404</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC566</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.86/32061</subfield><subfield code="2">20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YH 3015</subfield><subfield code="0">(DE-625)153535:12921</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Development of medications for the treatment of opiate and cocaine addictions</subfield><subfield code="b">issues for the government and private sector</subfield><subfield code="c">Committee to Study Medication Development and Research at the National Institute on Drug Abuse, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine. Carolyn E. Fulco ..., ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, DC</subfield><subfield code="b">National Acad. Press</subfield><subfield code="c">1995</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XVII, 250 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="610" ind1="2" ind2="4"><subfield code="a">National Institute on Drug Abuse</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cocaine abuse</subfield><subfield code="x">Treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cocaine</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug addiction</subfield><subfield code="x">Treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Legislation, Drug</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Narcotics</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Substance abuse</subfield><subfield code="x">Treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Substance-Related Disorders</subfield><subfield code="x">drug therapy</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cocain</subfield><subfield code="0">(DE-588)4128249-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Opiate</subfield><subfield code="0">(DE-588)4075669-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Drogentherapie</subfield><subfield code="0">(DE-588)4122122-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Drogenabhängigkeit</subfield><subfield code="0">(DE-588)4138597-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Drogenabhängigkeit</subfield><subfield code="0">(DE-588)4138597-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Opiate</subfield><subfield code="0">(DE-588)4075669-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Drogentherapie</subfield><subfield code="0">(DE-588)4122122-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Drogenabhängigkeit</subfield><subfield code="0">(DE-588)4138597-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Cocain</subfield><subfield code="0">(DE-588)4128249-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Drogentherapie</subfield><subfield code="0">(DE-588)4122122-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fulco, Carolyn E.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (Washington, DC)</subfield><subfield code="b">Committee to Study Medication Development and Research at the National Institute on Drug Abuse</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)1601098-X</subfield><subfield code="4">oth</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-007090681</subfield></datafield></record></collection> |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV010629404 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T17:56:14Z |
| institution | BVB |
| institution_GND | (DE-588)1601098-X |
| isbn | 0309052440 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-007090681 |
| oclc_num | 31944782 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | XVII, 250 S. graph. Darst. |
| publishDate | 1995 |
| publishDateSearch | 1995 |
| publishDateSort | 1995 |
| publisher | National Acad. Press |
| record_format | marc |
| spelling | Development of medications for the treatment of opiate and cocaine addictions issues for the government and private sector Committee to Study Medication Development and Research at the National Institute on Drug Abuse, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine. Carolyn E. Fulco ..., ed. Washington, DC National Acad. Press 1995 XVII, 250 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier National Institute on Drug Abuse Cocaine abuse Treatment Cocaine United States Drug Industry United States Drug addiction Treatment Legislation, Drug United States Narcotics United States Substance abuse Treatment Substance-Related Disorders drug therapy United States Cocain (DE-588)4128249-8 gnd rswk-swf Opiate (DE-588)4075669-5 gnd rswk-swf Drogentherapie (DE-588)4122122-9 gnd rswk-swf Drogenabhängigkeit (DE-588)4138597-4 gnd rswk-swf USA Drogenabhängigkeit (DE-588)4138597-4 s Opiate (DE-588)4075669-5 s Drogentherapie (DE-588)4122122-9 s DE-604 Cocain (DE-588)4128249-8 s Fulco, Carolyn E. Sonstige oth Institute of Medicine (Washington, DC) Committee to Study Medication Development and Research at the National Institute on Drug Abuse Sonstige (DE-588)1601098-X oth |
| spellingShingle | Development of medications for the treatment of opiate and cocaine addictions issues for the government and private sector National Institute on Drug Abuse Cocaine abuse Treatment Cocaine United States Drug Industry United States Drug addiction Treatment Legislation, Drug United States Narcotics United States Substance abuse Treatment Substance-Related Disorders drug therapy United States Cocain (DE-588)4128249-8 gnd Opiate (DE-588)4075669-5 gnd Drogentherapie (DE-588)4122122-9 gnd Drogenabhängigkeit (DE-588)4138597-4 gnd |
| subject_GND | (DE-588)4128249-8 (DE-588)4075669-5 (DE-588)4122122-9 (DE-588)4138597-4 |
| title | Development of medications for the treatment of opiate and cocaine addictions issues for the government and private sector |
| title_auth | Development of medications for the treatment of opiate and cocaine addictions issues for the government and private sector |
| title_exact_search | Development of medications for the treatment of opiate and cocaine addictions issues for the government and private sector |
| title_full | Development of medications for the treatment of opiate and cocaine addictions issues for the government and private sector Committee to Study Medication Development and Research at the National Institute on Drug Abuse, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine. Carolyn E. Fulco ..., ed. |
| title_fullStr | Development of medications for the treatment of opiate and cocaine addictions issues for the government and private sector Committee to Study Medication Development and Research at the National Institute on Drug Abuse, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine. Carolyn E. Fulco ..., ed. |
| title_full_unstemmed | Development of medications for the treatment of opiate and cocaine addictions issues for the government and private sector Committee to Study Medication Development and Research at the National Institute on Drug Abuse, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine. Carolyn E. Fulco ..., ed. |
| title_short | Development of medications for the treatment of opiate and cocaine addictions |
| title_sort | development of medications for the treatment of opiate and cocaine addictions issues for the government and private sector |
| title_sub | issues for the government and private sector |
| topic | National Institute on Drug Abuse Cocaine abuse Treatment Cocaine United States Drug Industry United States Drug addiction Treatment Legislation, Drug United States Narcotics United States Substance abuse Treatment Substance-Related Disorders drug therapy United States Cocain (DE-588)4128249-8 gnd Opiate (DE-588)4075669-5 gnd Drogentherapie (DE-588)4122122-9 gnd Drogenabhängigkeit (DE-588)4138597-4 gnd |
| topic_facet | National Institute on Drug Abuse Cocaine abuse Treatment Cocaine United States Drug Industry United States Drug addiction Treatment Legislation, Drug United States Narcotics United States Substance abuse Treatment Substance-Related Disorders drug therapy United States Cocain Opiate Drogentherapie Drogenabhängigkeit USA |
| work_keys_str_mv | AT fulcocarolyne developmentofmedicationsforthetreatmentofopiateandcocaineaddictionsissuesforthegovernmentandprivatesector AT instituteofmedicinewashingtondccommitteetostudymedicationdevelopmentandresearchatthenationalinstituteondrugabuse developmentofmedicationsforthetreatmentofopiateandcocaineaddictionsissuesforthegovernmentandprivatesector |